First-line bevacizumab (BEV) plus chemotherapy for hormone receptor-positive metastatic breast cancer (mBC): Subgroup analysis of the open-label non-inferiority TURANDOT phase III trial.

被引：1
|
作者：
Kahan, Zsuzsanna [1 ]
Petruzelka, Lubos [2 ]
Eniu, Alexandru [3 ]
Anghel, Rodica [4 ]
Koynov, Krassimir [5 ]
Vrbanec, Damir [6 ]
Lang, Istvan [7 ]
Ahlers, Silke [8 ]
Brodowicz, Thomas [9 ,10 ]
Zielinski, Christoph [9 ,10 ]
机构：
[1] Univ Szeged, Szeged, Hungary
[2] Charles Univ Prague, Prague, Czech Republic
[3] Inst Canc Res, Cluj Napoca, Romania
[4] Univ Med & Pharm Bucharest, Bucharest, Romania
[5] Univ Hosp, Sofia, Bulgaria
[6] Univ Hosp Rebro, Zagreb, Croatia
[7] Natl Inst Oncol, Budapest, Hungary
[8] IST GmbH, Mannheim, Germany
[9] Med Univ Vienna, Vienna, Austria
[10] CECOG, Vienna, Austria
来源：
CANCER RESEARCH | 2013年 / 73卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2013-LB-177
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB177
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial
    Yamada, Yasuhide
    Takahari, Daisuke
    Matsumoto, Hiroshi
    Baba, Hideo
    Nakamura, Masato
    Yoshida, Kazuhiro
    Yoshida, Motoki
    Iwamoto, Shigeyoshi
    Shimada, Ken
    Komatsu, Yoshito
    Sasaki, Yasutsuna
    Satoh, Taroh
    Takahashi, Keiichi
    Mishima, Hideyuki
    Muro, Kei
    Watanabe, Masahiko
    Sakata, Yuh
    Morita, Satoshi
    Shimada, Yasuhiro
    Sugihara, Kenichi
    LANCET ONCOLOGY, 2013, 14 (13): : 1278 - 1286
  • [32] Phase I/II study of letrozole and sorafenib as first-line therapy of hormone-receptor positive (HR plus ) metastatic breast cancer (MBC).
    Tan, Antoinette R.
    Wong, Serena Tsan-Lai
    Warren, Robert D.
    Eng-Wong, Jennifer
    Liu, Minetta C.
    Zelnak, Amelia Bruce
    Lin, Yong
    Shih, Weichung
    Ganesan, Shridar
    Grana, Generosa
    Isaacs, Claudine
    Toppmeyer, Deborah
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [33] Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial
    von Minckwitz, Gunter
    Puglisi, Fabio
    Cortes, Javier
    Vrdoljak, Eduard
    Marschner, Norbert
    Zielinski, Christoph
    Villanueva, Cristian
    Romieu, Gilles
    Lang, Istvan
    Ciruelos, Eva
    De laurentiis, Michele
    Veyret, Corinne
    de Ducla, Sabine
    Freudensprung, Ulrich
    Srock, Stefanie
    Gligorov, Joseph
    LANCET ONCOLOGY, 2014, 15 (11): : 1269 - 1278
  • [34] Randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer (mCRC), comparing the efficacy and safety of XELIRI plus bevacizumab versus FOLFIRI plus bevacizumab (AXEPT)
    Kim, T. W.
    Park, Y. S.
    Muro, K.
    Xu, R.
    Han, S.
    Yamazaki, K.
    Wang, W.
    Ahn, J. B.
    Uetake, H.
    Deng, Y.
    Cho, S.
    Matsumoto, H.
    Ba, Y.
    Lee, K-W.
    Nishina, T.
    Zhang, T.
    Iwasa, S.
    Morita, S.
    Sakamoto, J.
    ANNALS OF ONCOLOGY, 2017, 28 : 186 - 186
  • [35] First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients
    Smith, I. E.
    Pierga, J. -Y.
    Biganzoli, L.
    Cortes-Funes, H.
    Thomssen, C.
    Pivot, X.
    Fabi, A.
    Xu, B.
    Stroyakovskiy, D.
    Franke, F. A.
    Kaufman, B.
    Mainwaring, P.
    Pienkowski, T.
    De Valk, B.
    Kwong, A.
    Gonzalez-Trujillo, J. L.
    Koza, I.
    Petrakova, K.
    Pereira, D.
    Pritchard, K. I.
    ANNALS OF ONCOLOGY, 2011, 22 (03) : 595 - 602
  • [36] Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial
    Lang, I.
    Inbar, M.
    Steger, G.
    Greil, R.
    Zvirbule, Z.
    Beslija, S.
    Kahan, Z.
    Taskova, V.
    Kaufmann, B.
    Zielinski, C. C.
    EJC SUPPLEMENTS, 2009, 7 (02): : 277 - 278
  • [37] Oral S-1 with 24-h Infusion of Irinotecan plus Bevacizumab versus FOLFIRI plus Bevacizumab as First-Line Chemotherapy for Metastatic Colorectal Cancer: An Open-Label Randomized Phase II Trial
    Sadahiro, Sotaro
    Suzuki, Toshiyuki
    Okada, Kazutake
    Saito, Gota
    Miyakita, Hiroshi
    Ogimi, Takashi
    Chan, Lin Fung
    Kamei, Yutaro
    ONCOLOGY, 2020, 98 (09) : 637 - 642
  • [38] Efficacy and safety of paclitaxel liposome versus paclitaxel in combination with carboplatin in the first-line chemotherapy for ovarian cancer: a multicenter, open-label, non-inferiority, randomized controlled trial
    Li, Rong
    Zhang, Hongping
    Li, Qingshui
    Yuan, Guangwen
    Zhou, Yanjie
    Yin, Rutie
    Wang, He
    Wang, Chunyan
    Huang, Yi
    Wang, Wei
    Yan, Xiaojian
    Wu, Lingying
    Zhou, Qi
    JOURNAL OF THE NATIONAL CANCER CENTER, 2024, 4 (02): : 135 - 141
  • [39] An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer
    Esteva, Francisco J.
    Franco, Sandra X.
    Hagan, Maura K.
    Brewster, Abenaa M.
    Somer, Robert A.
    Williams, Will
    Florance, Allison M.
    Turner, Simon
    Stein, Steven
    Perez, Alejandra
    ONCOLOGIST, 2013, 18 (06): : 661 - 666
  • [40] Induction treatment in first-line with chemotherapy plus bevacizumab (bev) in metastatic colorectal cancer: Results from the gercor-DREAM phase III study
    Tournigand, Christophe
    Scheithauer, Werner
    Samson, Benoit
    Lledo, Gerard
    Viret, Frederic
    Andre, Thierry
    Ramee, Jean Francois
    Tubiana-Mathieu, Nicole
    Dauba, Jerome
    Dupuis, Olivier
    Rinaldi, Yves
    Mabro, May
    Aucoin, Nathalie
    Khalil, Ahmed
    Latreille, Jean
    Louvet, Christophe
    Brusquant, David
    Bonnetain, Franck
    Chibaudel, Benoist
    De Gramont, Aimery
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
12345